|
|
|
This is the preliminary program for the 2009 Joint Statistical
Meetings in Washington, DC.
|
|
|
The views expressed here are those of the individual authors and not necessarily those of the ASA or its board, officers, or staff. Back to main JSM 2009 Program page |
= Applied Session,
= Theme Session,
= Presenter
599
|
Thu, 8/6/09, 10:30 AM - 12:20 PM | CC-144A |
| Issues Related to Surrogate Endpoints, Biomarkers, and Survival Analysis - Contributed - Papers | ||
|
Biopharmaceutical Section |
||
| Chair(s): B. Christine Clark, ReSearch Pharmaceutical Services, Inc. | ||
| 10:35 AM |
Adjustment for the Measurement Error in Evaluating Biomarkers —  Wen Li, Iowa State University; Yongming Qu, Eli Lilly and Company
|
|
| 10:50 AM |
Efficiency Impact of Proportional Hazards Assumption Violation — Amarjot Kaur, Merck & Co., Inc.; Yabing Mai, FDA
|
|
| 11:05 AM |
Effect of Predictive Performance of a Biomarker for the Sample Size of Targeted Clinical Trials — Xiwu Lin, GlaxoSmithKline; Daniel Parks, GlaxoSmithKline; Kwan R. Lee, GlaxoSmithKline
|
|
| 11:20 AM |
An Assessment of Several Trial-Level Surrogacy Measures in the Meta-Analytical Framework of Evaluating Surrogate Endpoints in Clinical Trials — Qian Shi, Mayo Clinic; Daniel Sargent, Mayo Clinic
|
|
| 11:35 AM |
Comparison of Vaccine Effects of LAIV and TIV on Pneumonia and Influenza-Related Medical Encounters — Jean A. Roayaei, National Institutes of Health
|
|
| 12:05 PM | Floor Discussion | |
|
JSM 2009
For information, contact jsm@amstat.org
or phone (888) 231-3473. If you have questions about the Continuing Education program,
please contact the Education Department. |